Lupin and Natco get FDA approval for Eribulin Mesylate injection

Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.

Glenmark posts strong FY26 results with 27.5% revenue jump

Lupin secures FDA nod for generic Sutab tablets with 180-day exclusivity

The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals

Glenmark Pharma appoints Shisher Chowksey as Head of Marketing

In his new role, Shisher will lead Glenmark’s marketing initiatives, focusing on strengthening brand positioning, driving market expansion, and accelerating growth

EU regulator backs Allergan Aesthetics’ Boey in key step toward approval

The decision marks a key step in the centralized EU review process

Alembic Pharma receives USFDA nod for generic Levothyroxine sodium tablets

Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism

Lupin enters China market with approval for Oseltamivir oral suspension

The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment

Apothecon Pharma appoints Shyamakant Giri as Group CEO

In his new role, he will lead the growth strategy for the group’s operations, including Apothecon Pharmaceuticals in India and Navinta LLC in the United States

Lupin gets tentative FDA nod for Revefenacin inhalation solution

The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)

IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027